JP2009536627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536627A5 JP2009536627A5 JP2009508191A JP2009508191A JP2009536627A5 JP 2009536627 A5 JP2009536627 A5 JP 2009536627A5 JP 2009508191 A JP2009508191 A JP 2009508191A JP 2009508191 A JP2009508191 A JP 2009508191A JP 2009536627 A5 JP2009536627 A5 JP 2009536627A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- bond
- alkylene
- alkynylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*1=CC=CC(c(nc(N(*)**)nc2)c2-c2ccccc2)=CC1 Chemical compound C*1=CC=CC(c(nc(N(*)**)nc2)c2-c2ccccc2)=CC1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006021874.4 | 2006-05-11 | ||
| DE102006021874A DE102006021874B4 (de) | 2006-05-11 | 2006-05-11 | 4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| PCT/EP2007/003804 WO2007131620A1 (de) | 2006-05-11 | 2007-04-30 | 4,5-diphenyl-pyrimidinyl-amino substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009536627A JP2009536627A (ja) | 2009-10-15 |
| JP2009536627A5 true JP2009536627A5 (enExample) | 2013-05-16 |
| JP5277159B2 JP5277159B2 (ja) | 2013-08-28 |
Family
ID=38326940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009508191A Expired - Fee Related JP5277159B2 (ja) | 2006-05-11 | 2007-04-30 | ４，５−ジフェニル−ピリミジニルアミノ置換カルボン酸類、それらの製造方法及び医薬品としての使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7713988B2 (enExample) |
| EP (1) | EP2024340B1 (enExample) |
| JP (1) | JP5277159B2 (enExample) |
| KR (1) | KR20090006845A (enExample) |
| CN (1) | CN101421251B (enExample) |
| AR (1) | AR060992A1 (enExample) |
| AU (1) | AU2007250211B2 (enExample) |
| BR (1) | BRPI0711393A2 (enExample) |
| CA (1) | CA2651657A1 (enExample) |
| DE (1) | DE102006021874B4 (enExample) |
| IL (1) | IL195177A0 (enExample) |
| MX (1) | MX2008014101A (enExample) |
| MY (1) | MY148096A (enExample) |
| NO (1) | NO20085066L (enExample) |
| TW (1) | TW200815366A (enExample) |
| UY (1) | UY30339A1 (enExample) |
| WO (1) | WO2007131620A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| US7582803B2 (en) | 2005-09-14 | 2009-09-01 | Amgen Inc. | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders |
| CA2662305C (en) | 2006-09-07 | 2012-04-17 | Amgen Inc. | Heterocyclic gpr40 modulators |
| EP2061760A1 (en) | 2006-09-07 | 2009-05-27 | Amgen, Inc | Benzo-fused compounds for use in treating metabolic disorders |
| ES2446419T3 (es) | 2007-04-16 | 2014-03-07 | Amgen, Inc | Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP5591706B2 (ja) | 2007-10-10 | 2014-09-17 | アムジエン・インコーポレーテツド | 置換ビフェニルｇｐｒ４０調節因子 |
| WO2009111056A1 (en) | 2008-03-06 | 2009-09-11 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
| AU2009303475B2 (en) | 2008-10-15 | 2012-09-13 | Amgen Inc. | Spirocyclic GPR40 modulators |
| MX2011006006A (es) * | 2008-12-08 | 2011-09-08 | Euroscreen Sa | Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos. |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8450350B2 (en) | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
| CA2798330A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| CN103298469A (zh) | 2010-08-31 | 2013-09-11 | 首尔大学校产学协力财团 | PPARδ激动剂的胎儿重编程的用途 |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN105142621A (zh) | 2012-10-24 | 2015-12-09 | 国家健康科学研究所 | 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂 |
| WO2015084692A1 (en) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10059667B2 (en) | 2014-02-06 | 2018-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| EP3273981B1 (en) | 2015-03-24 | 2020-04-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of diabetes |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003275242B2 (en) * | 2002-09-27 | 2010-03-04 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| NZ550114A (en) * | 2004-04-20 | 2011-02-25 | Transtech Pharma Inc | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
| DE102004039789A1 (de) * | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
-
2006
- 2006-05-11 DE DE102006021874A patent/DE102006021874B4/de not_active Expired - Fee Related
-
2007
- 2007-04-30 BR BRPI0711393-5A patent/BRPI0711393A2/pt not_active IP Right Cessation
- 2007-04-30 WO PCT/EP2007/003804 patent/WO2007131620A1/de not_active Ceased
- 2007-04-30 KR KR1020087027548A patent/KR20090006845A/ko not_active Abandoned
- 2007-04-30 JP JP2009508191A patent/JP5277159B2/ja not_active Expired - Fee Related
- 2007-04-30 EP EP07724731A patent/EP2024340B1/de not_active Not-in-force
- 2007-04-30 AU AU2007250211A patent/AU2007250211B2/en not_active Ceased
- 2007-04-30 CA CA002651657A patent/CA2651657A1/en not_active Abandoned
- 2007-04-30 CN CN2007800133035A patent/CN101421251B/zh not_active Expired - Fee Related
- 2007-04-30 MX MX2008014101A patent/MX2008014101A/es not_active Application Discontinuation
- 2007-05-09 AR ARP070102010A patent/AR060992A1/es not_active Application Discontinuation
- 2007-05-09 TW TW096116359A patent/TW200815366A/zh unknown
- 2007-05-10 UY UY30339A patent/UY30339A1/es not_active Application Discontinuation
-
2008
- 2008-11-06 MY MYPI20084448A patent/MY148096A/en unknown
- 2008-11-09 IL IL195177A patent/IL195177A0/en unknown
- 2008-11-10 US US12/267,918 patent/US7713988B2/en not_active Expired - Fee Related
- 2008-12-04 NO NO20085066A patent/NO20085066L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536626A5 (enExample) | ||
| JP2009536629A5 (enExample) | ||
| Soare et al. | Dipeptidylpeptidase 4 as a marker of activated fibroblasts and a potential target for the treatment of fibrosis in systemic sclerosis | |
| RU2008148838A (ru) | Фениламинобензоксазолзамещенные карбоновые кислоты, способ их получения и их применение в качестве лекарственных средств | |
| Huang et al. | ER stress, the unfolded protein response and osteoclastogenesis: a review | |
| Huang et al. | Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro | |
| JP2005501861A5 (enExample) | ||
| RU2010115748A (ru) | (карбоксилалкиленфенил) фенилоксаламиды, способ их получения и их применение в качестве лекарственного средства | |
| Lin et al. | Growth hormone receptor mutations related to individual dwarfism | |
| Shams et al. | The pathophysiology of osteoporosis after spinal cord injury | |
| Pei et al. | Fluoride decreased osteoclastic bone resorption through the inhibition of NFATc1 gene expression | |
| RU2008105756A (ru) | Производные 1,4-бензотиазепин-1,1-диоксида, способ их получения, лекарственное средство, содержащее эти соединения и их применение в качестве гиполипидемических средств | |
| RU2009108280A (ru) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение | |
| JP2000509395A (ja) | 無機イオン活性化合物 | |
| RU2009122470A (ru) | Новые бензилзамещенные производные 1,4-бензотиепин-1,1-диоксида, способ их получения, лекарственные средства, содержащие такие соединения, и их применение | |
| Kim et al. | Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression | |
| JP2006502247A5 (enExample) | ||
| RU2007142657A (ru) | Производные азола в качестве ингибиторов липаз и фосфолипаз | |
| JP2007500145A5 (enExample) | ||
| JP2008536884A5 (enExample) | ||
| CN101090895A (zh) | 芳基磺酰胺调节剂 | |
| Kruse et al. | Novel insights into M3 muscarinic acetylcholine receptor physiology and structure | |
| Tong et al. | A review of signaling transduction mechanisms in osteoclastogenesis regulation by autophagy, inflammation, and immunity | |
| Okita et al. | Supplementation of strontium to a chondrogenic medium promotes chondrogenic differentiation of human dedifferentiated fat cells | |
| Lin et al. | Alteration of bone cell function by RANKL and OPG in different in vitro models |